Skip to main content


47Sc as useful β–-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes

Winner of the journal’s Best Paper Award 2018

A comparison between two methods of 47Sc production, based on the neutron irradiation of enriched 46Ca and 47Ti targets. The 46Ca(n,γ)47Ca nuclear reaction provided higher quantities of a radionuclidically pure product, demonstrating a significant advantage over the 47Ti production method.

Congratulations to the authors: Katharina A. Domnanich, Cristina Müller, Martina Benešová, Rugard Dressler, Stephanie Haller, Ulli Köster, Bernard Ponsard, Roger Schibli, Andreas Türler and Nicholas P. van der Meulen!

The award was presented at the EANM Congress 2018. 


  1. Authors: V. Radchenko, J. W. Engle, C. Roy, J. Griswold, M. F. Nortier, E. R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M. E. Fassbender, Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo, Ait-Mohand Samia…

    Content type: Meeting abstracts

Check if your institution is a member

More than 500 institutions have partnered with BMC through the membership program. As an affiliated Author from a member institution, you may be entitled to submit your manuscript without paying the article processing charge (APC) or with a discount. Check here if your institution is a member!

EANM Sponsorship Programme

The EANM Board decided to allocate funds to a dedicated Publication Fee Sponsorship Programme for the selected journals in the  EJNMMI journal family. Through this programme, the EANM will cover the charges that arise for publications in the open access journals EJNMMI Physics, EJNMMI Radiopharmacy and Chemistry and the European Journal of Hybrid Imaging. Find out more here.

Aims and scope

EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide-based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight into novel concepts of imaging or radionuclide-based therapeutic agent applications of relevance for the whole molecular imaging community.

The journal reports original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in the form of guidelines or position papers.

EJNMMI Journal Family

EJNMMI GatewayDiscover featured content, editor’s highlights, and the latest research via our Gateway to the EJNMMI Journal Family

Need help with APC funding?

New Content Item

We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. ​​​​​​​Learn more here.

EJNMMI Radiopharmacy and Chemistry is a new journal within the EJNMMI family to publish research in the field of new imaging and radionuclide-based therapeutic agents that can be applied in nuclear medicine and molecular imaging. There is a great need for better and more specific imaging agents for better diagnosis and understanding of disease. This will finally enable improvement of patient treatment. The combination of different molecular imaging modalities to obtain the optimal diagnostic information will be bolstered by the development of hybrid imaging probes. The number of applications of radionuclide therapy is increasing and more effective radiotherapeutic agents are urgently needed. Thus it can be concluded that radiopharmacy and radiochemistry are very essential for the development of nuclear medicine and molecular imaging and for its position in personalized medicine.

This new journal provides an ideal platform for chemists, pharmacists and basic scientists to promote science, but also to exchange opinions and to provide updates on developments that have an effect on the availability of imaging agents for the clinic, such as regulatory aspects. By accepting original research articles, review papers, guidelines on the application of imaging or radionuclide therapy agents, editorials, and letters to the editor I hope to establish a unique platform for our community.

Philip H. Elsinga, Editor-in-Chief University of Groningen


Affiliated with

Annual Journal Metrics

  • Speed
    41 days to first decision for reviewed manuscripts only
    41 days to first decision for all manuscripts
    75 days from submission to acceptance
    28 days from acceptance to publication